Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Stephen Howell

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Anatomy

Cultured Tumor Cells

Physiology

Phenomena

Drug Synergism

Procedures

Living Beings

Mice

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
31
Christen, RD
19
Kirmani, S
19
McClay, EF
18
Fink, D
18
Los, Gerrit
17
Safaei, Roohangiz
17
Lin, Xinjian
16
Samimi, Goli
16
Aebi, Stefan
13
Jones, Jeffrey
12
Holzer, Alison
11
Plaxe, Steven
10
Katano, Kuniyuki
9
Jekunen, Antti
9
Nebel, S

Sign-in to see all Coauthors

Publications

TOP 3
Jandial Danielle D; Messer Karen; Farshchi-Heydari Salman; Pu Minya; Howell Stephen B
Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
Yuan Xiaoqin; Lin Xinjian; Manorek Gerald; Kanatani Isao; Cheung Lawrence H; Rosenblum Michael G; Howell Stephen B
Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors.
Blair Brian G; Larson Christopher A; Safaei Roohangiz; Howell Stephen B
Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Stephen Howell (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Jandial Danielle D; Messer Karen; Farshchi-Heydari Salman; Pu Minya; Howell Stephen B
Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
Gynecologic oncology 2009;115(3):362-6.
2009: Yuan Xiaoqin; Lin Xinjian; Manorek Gerald; Kanatani Isao; Cheung Lawrence H; Rosenblum Michael G; Howell Stephen B
Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors.
Molecular cancer therapeutics 2009;8(7):1906-15.
2009: Blair Brian G; Larson Christopher A; Safaei Roohangiz; Howell Stephen B
Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(13):4312-21.
2009: Safaei Roohangiz; Maktabi Mohammad H; Blair Brian G; Larson Christopher A; Howell Stephen B
Effects of the loss of Atox1 on the cellular pharmacology of cisplatin.
Journal of inorganic biochemistry 2009;103(3):333-41.
2009: Larson Christopher A; Blair Brian G; Safaei Roohangiz; Howell Stephen B
The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.
Molecular pharmacology 2009;75(2):324-30.
2009: Jandial Danielle D; Farshchi-Heydari Salman; Larson Christopher A; Elliott Gregory I; Wrasidlo Wolfgang J; Howell Stephen B
Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(2):553-60.
2008: Howell S B
Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18 Suppl 1():20-5.
2008: Safaei Roohangiz; Otani Shinji; Larson Barrett J; Rasmussen Michael L; Howell Stephen B
Transport of cisplatin by the copper efflux transporter ATP7B.
Molecular pharmacology 2008;73(2):461-8.
2007: Lee Sangwon; Howell Stephen B; Opella Stanley J
NMR and mutagenesis of human copper transporter 1 (hCtr1) show that Cys-189 is required for correct folding and dimerization.
Biochimica et biophysica acta 2007;1768(12):3127-34.
2007: Campone Mario; Rademaker-Lakhai Jeany M; Bennouna Jaafar; Howell Stephen B; Nowotnik David P; Beijnen Jos H; Schellens Jan H M
Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Cancer chemotherapy and pharmacology 2007;60(4):523-33.
2007: Kong Seong Deok; Luong Alice; Manorek Gerald; Howell Stephen B; Yang Jerry
Acidic hydrolysis of N-Ethoxybenzylimidazoles (NEBIs): potential applications as pH-sensitive linkers for drug delivery.
Bioconjugate chemistry 2007;18(2):293-6.
2007: Samimi Goli; Kishimoto Shuichi; Manorek Gerald; Breaux James K; Howell Stephen B
Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Cancer chemotherapy and pharmacology 2007;59(3):301-12.
2006: Holzer Alison K; Howell Stephen B
The internalization and degradation of human copper transporter 1 following cisplatin exposure.
Cancer research 2006;66(22):10944-52.
2006: Holzer Alison K; Manorek Gerald H; Howell Stephen B
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Molecular pharmacology 2006;70(4):1390-4.
2006: Cheng Timothy C; Manorek Gerald; Samimi Goli; Lin Xinjian; Berry Charles C; Howell Stephen B
Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.
Cancer chemotherapy and pharmacology 2006;58(3):384-95.
2006: Samimi Goli; Howell Stephen B
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Cancer chemotherapy and pharmacology 2006;57(6):781-8.
2006: Lin Xinjian; Howell Stephen B
DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance.
Molecular cancer therapeutics 2006;5(5):1239-47.
2006: Lin Xinjian; Okuda Tsuyoshi; Trang Julie; Howell Stephen B
Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells.
Molecular pharmacology 2006;69(5):1748-54.
2006: Rice John R; Gerberich Jennifer L; Nowotnik David P; Howell Stephen B
Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2248-54.
2006: Lin Xinjian; Trang Julie; Okuda Tsuyoshi; Howell Stephen B
DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(2):563-8.
2005: Safaei Roohangiz; Larson Barrett J; Cheng Timothy C; Gibson Michael A; Otani Shinji; Naerdemann Wiltrud; Howell Stephen B
Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells.
Molecular cancer therapeutics 2005;4(10):1595-604.
2005: Okuda Tsuyoshi; Lin Xinjian; Trang Julie; Howell Stephen B
Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin.
Molecular pharmacology 2005;67(6):1852-60.
2005: Safaei Roohangiz; Katano Kuniyuki; Larson Barrett J; Samimi Goli; Holzer Alison K; Naerdemann Wiltrud; Tomioka Mika; Goodman Murray; Howell Stephen B
Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):756-67.
2005: Safaei Roohangiz; Howell Stephen B
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
Critical reviews in oncology/hematology 2005;53(1):13-23.
2005: Samimi Goli; Manorek Gerald; Castel Rob; Breaux James K; Cheng Tim C; Berry Charles C; Los Gerrit; Howell Stephen B
cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance.
Cancer chemotherapy and pharmacology 2005;55(1):1-11.
2004: Wu Fang; Lin Xinjian; Okuda Tsuyoshi; Howell Stephen B
DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance.
Cancer research 2004;64(21):8029-35.
2004: Holzer Alison K; Katano Kuniyuki; Klomp Leo W J; Howell Stephen B
Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6744-9.
2004: Safaei Roohangiz; Holzer Alison K; Katano Kuniyuki; Samimi Goli; Howell Stephen B
The role of copper transporters in the development of resistance to Pt drugs.
Journal of inorganic biochemistry 2004;98(10):1607-13.
2004: Holzer Alison K; Samimi Goli; Katano Kuniyuki; Naerdemann Wiltrud; Lin Xinjian; Safaei Roohangiz; Howell Stephen B
The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.
Molecular pharmacology 2004;66(4):817-23.
2004: Samimi Goli; Safaei Roohangiz; Katano Kuniyuki; Holzer Alison K; Rochdi Myriam; Tomioka Mika; Goodman Murray; Howell Stephen B
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4661-9.
2004: Katano Kuniyuki; Safaei Roohangiz; Samimi Goli; Holzer Alison; Tomioka Mika; Goodman Murray; Howell Stephen B
Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4578-88.
2004: Samimi Goli; Katano Kuniyuki; Holzer Alison K; Safaei Roohangiz; Howell Stephen B
Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Molecular pharmacology 2004;66(1):25-32.
2004: Rademaker-Lakhai Jeany M; Terret Catherine; Howell Stephen B; Baud Christiane M; De Boer Richard F; Pluim Dick; Beijnen Jos H; Schellens Jan H M; Droz Jean-Pierre
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3386-95.
2004: Safaei Roohangiz; Katano Kuniyuki; Samimi Goli; Naerdemann Wiltrud; Stevenson Jennifer L; Rochdi Myriam; Howell Stephen B
Cross-resistance to cisplatin in cells with acquired resistance to copper.
Cancer chemotherapy and pharmacology 2004;53(3):239-46.
2004: Lin X; Zhang Q; Rice J R; Stewart D R; Nowotnik D P; Howell S B
Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models.
European journal of cancer (Oxford, England : 1990) 2004;40(2):291-7.
2003: Samimi Goli; Varki Nissi M; Wilczynski Sharon; Safaei Roohangiz; Alberts David S; Howell Stephen B
Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(16 Pt 1):5853-9.
2003: Katano Kuniyuki; Safaei Roohangiz; Samimi Goli; Holzer Alison; Rochdi Myriam; Howell Stephen B
The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells.
Molecular pharmacology 2003;64(2):466-73.
2003: Cruz-Monserrate Zobeida; Vervoort Hélène C; Bai Ruoli; Newman David J; Howell Stephen B; Los Gerrit; Mullaney Jeffrey T; Williams Michael D; Pettit George R; Fenical William; Hamel Ernest
Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.
Molecular pharmacology 2003;63(6):1273-80.
2002: Katano Kuniyuki; Kondo Akira; Safaei Roohangiz; Holzer Alison; Samimi Goli; Mishima Misako; Kuo Yien-Ming; Rochdi Myriam; Howell Stephen B
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
Cancer research 2002;62(22):6559-65.
2002: de las Alas Maida M; Los Gerrit; Lin Xinjian; Kurdi-Haidar Buran; Manorek Gerald; Howell Stephen B
Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanine.
Molecular pharmacology 2002;62(5):1198-206.
2002: Lin Xinjian; Okuda Tsuyoshi; Holzer Alison; Howell Stephen B
The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.
Molecular pharmacology 2002;62(5):1154-9.
2002: Mishima M; Samimi G; Kondo A; Lin X; Howell S B
The cellular pharmacology of oxaliplatin resistance.
European journal of cancer (Oxford, England : 1990) 2002;38(10):1405-12.
2001: Niedner H; Christen R; Lin X; Kondo A; Howell S B
Identification of genes that mediate sensitivity to cisplatin.
Molecular pharmacology 2001;60(6):1153-60.
2001: Kondo A; Safaei R; Mishima M; Niedner H; Lin X; Howell S B
Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair.
Cancer research 2001;61(20):7603-7.
2001: Lin X; Gately D P; Hom D; Mishima M; Los G; Howell S B
Quantification of tumor cell injury in vitro and in vivo using expression of green fluorescent protein under the control of the GADD153 promoter.
International journal of cancer. Journal international du cancer 2001;91(4):555-62.
2001: Lin X; Ramamurthi K; Mishima M; Kondo A; Christen R D; Howell S B
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Cancer research 2001;61(4):1508-16.
2000: Lin X; Ramamurthi K; Mishima M; Kondo A; Howell S B
p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide.
Molecular pharmacology 2000;58(6):1222-9.
2000: Johnsson A; Zeelenberg I; Min Y; Hilinski J; Berry C; Howell S B; Los G
Identification of genes differentially expressed in association with acquired cisplatin resistance.
British journal of cancer 2000;83(8):1047-54.
2000: Samimi G; Fink D; Varki N M; Husain A; Hoskins W J; Alberts D S; Howell S B
Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1415-21.
2000: de las Alas M M; Christen R D; Gately D P; Weiner D E; Benbatoul K; Kirmani S; D'Agostino H R; Plaxe S C; Darrah D; McClay E F; Aebi S; Howell S B; Los G
Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel.
Cancer chemotherapy and pharmacology 2000;45(5):381-8.
1999: Lin X; Kim H K; Howell S B
The role of DNA mismatch repair in cisplatin mutagenicity.
Journal of inorganic biochemistry 1999;77(1-2):89-93.
1999: Scheeff E D; Briggs J M; Howell S B
Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin.
Molecular pharmacology 1999;56(3):633-43.
1999: Lin X; Howell S B
Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin.
Molecular pharmacology 1999;56(2):390-5.
1999: Los G; Benbatoul K; Gately D P; Barton R; Christen R; Robbins K T; Vicario D; Kirmani S; Orloff L A; Weisman R; Howell S B
Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1610-8.
1999: Carethers J M; Chauhan D P; Fink D; Nebel S; Bresalier R S; Howell S B; Boland C R
Mismatch repair proficiency and in vitro response to 5-fluorouracil.
Gastroenterology 1999;117(1):123-31.
1999: Cenni B; Kim H K; Bubley G J; Aebi S; Fink D; Teicher B A; Howell S B; Christen R D
Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
British journal of cancer 1999;80(5-6):699-704.
1999: Ferry K V; Fink D; Johnson S W; Nebel S; Hamilton T C; Howell S B
Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells.
Biochemical pharmacology 1999;57(8):861-7.
1999: Nehmé A; Baskaran R; Nebel S; Fink D; Howell S B; Wang J Y; Christen R D
Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
British journal of cancer 1999;79(7-8):1104-10.
1999: Aebi S; Schnider T W; Los G; Heath D D; Darrah D; Kirmani S; McClay E F; D'Agostino H; Plaxe S C; Fink D; De las Alas M M; Howell S B; Christen R D
A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel.
Cancer chemotherapy and pharmacology 1999;44(3):259-65.
1998: Kurdi-Haidar B; Heath D; Naredi P; Varki N; Howell S B
Immunohistochemical analysis of the distribution of the human ATPase (hASNA-I) in normal tissues and its overexpression in breast adenomas and carcinomas.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1998;46(11):1243-8.
1998: Kurdi-Haidar B; Hom D K; Flittner D E; Heath D; Fink L; Naredi P; Howell S B
Dual cytoplasmic and nuclear distribution of the novel arsenite-stimulated human ATPase (hASNA-I).
Journal of cellular biochemistry 1998;71(1):1-10.
1998: Kurdi-Haidar B; Heath D; Lennon G; Howell S B
Chromosomal localization and genomic structure of the human arsenite-stimulated ATPase (hASNA-I).
Somatic cell and molecular genetics 1998;24(5):307-11.
1998: Kurdi-Haidar B; Heath D; Aebi S; Howell S B
Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I).
The Journal of biological chemistry 1998;273(35):22173-6.
1998: Fink D; Nebel S; Norris P S; Baergen R N; Wilczynski S P; Costa M J; Haas M; Cannistra S A; Howell S B
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin.
International journal of cancer. Journal international du cancer 1998;77(5):741-6.
1998: de las Alas M M; de Bruin R A; Ten Eyck L; Los G; Howell S B
Prediction-based threading of the hMSH2 DNA mismatch repair protein.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1998;12(9):653-63.
1998: Fink D; Nebel S; Norris P S; Aebi S; Kim H K; Haas M; Howell S B
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.
British journal of cancer 1998;77(5):703-8.
1998: Fink D; Aebi S; Howell S B
The role of DNA mismatch repair in drug resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):1-6.
1998: Plaxe S C; Christen R D; O'Quigley J; Braly P S; Freddo J L; McClay E; Heath D; Howell S B
Phase I and pharmacokinetic study of intraperitoneal topotecan.
Investigational new drugs 1998;16(2):147-53.
1997: Aebi S; Kröning R; Cenni B; Sharma A; Fink D; Los G; Weisman R; Howell S B; Christen R D
all-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2033-8.
1997: Aebi S; Fink D; Gordon R; Kim H K; Zheng H; Fink J L; Howell S B
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1763-7.
1997: de las Alas M M; Aebi S; Fink D; Howell S B; Los G
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.
Journal of the National Cancer Institute 1997;89(20):1537-41.
1997: Zheng H; Fink D; Li H; Jiang X; Aebi S; Law P; Goodman M; Howell S B
In vitro antineoplastic activity of a novel lanthionine-containing peptide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(8):1323-30.
1997: Nehmé A; Baskaran R; Aebi S; Fink D; Nebel S; Cenni B; Wang J Y; Howell S B; Christen R D
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin.
Cancer research 1997;57(15):3253-7.
1997: Zheng H; Fink D; Howell S B
Pharmacological basis for a novel therapeutic strategy based on the use of aquated cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(7):1157-65.
1997: Jones J A; Albright K D; Christen R D; Howell S B; McClay E F
Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites.
Cancer research 1997;57(13):2657-60.
1997: Fink D; Zheng H; Nebel S; Norris P S; Aebi S; Lin T P; Nehmé A; Christen R D; Haas M; MacLeod C L; Howell S B
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Cancer research 1997;57(10):1841-5.
1997: McClay E F; McClay M E; Jones J A; Winski P J; Christen R D; Howell S B; Hall P D
A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma.
Cancer 1997;79(5):1037-43.
1997: Perego P; Vande Weghe J; Ow D W; Howell S B
Role of determinants of cadmium sensitivity in the tolerance of Schizosaccharomyces pombe to cisplatin.
Molecular pharmacology 1997;51(1):12-8.
1997: Fink D; Nebel S; Aebi S; Zheng H; Kim H K; Christen R D; Howell S B
Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues.
British journal of cancer 1997;76(7):890-3.
1996: Perego P; Jimenez G; Howell S B
Isolation and characterization of a cisplatin-resistant strain of Schizosaccharomyces pombe.
Molecular pharmacology 1996;50(5):1080-6.
1996: Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen R D; Howell S B
The role of DNA mismatch repair in platinum drug resistance.
Cancer research 1996;56(21):4881-6.
1996: Kurdi-Haidar B; Aebi S; Heath D; Enns R E; Naredi P; Hom D K; Howell S B
Isolation of the ATP-binding human homolog of the arsA component of the bacterial arsenite transporter.
Genomics 1996;36(3):486-91.
1996: McClay E F; Jones J A; Winski P J; Albright K D; Christen R D; Howell S B
Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
Cancer research 1996;56(17):3993-7.
1996: Robbins K T; Fontanesi J; Wong F S; Vicario D; Seagren S; Kumar P; Weisman R; Pellitteri P; Thomas J R; Flick P; Palmer R; Weir A; Kerber C; Murry T; Ferguson R; Los G; Orloff L; Howell S B
A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx.
Archives of otolaryngology--head & neck surgery 1996;122(8):853-7.
1996: Gately D P; Howell S B
Paclitaxel activation of the GADD153 promoter through a cellular injury response element containing an essential Sp1 binding site.
The Journal of biological chemistry 1996;271(34):20588-93.
1996: Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen R D; Boland C R; Koi M; Fishel R; Howell S B
Loss of DNA mismatch repair in acquired resistance to cisplatin.
Cancer research 1996;56(13):3087-90.
1996: Gately D P; Sharma A; Christen R D; Howell S B
Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153.
British journal of cancer 1996;73(1):18-23.
1996: Robbins K T; Storniolo A M; Hryniuk W M; Howell S B
"Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. II. Clinical studies.
The Laryngoscope 1996;106(1 Pt 1):37-42.
1995: Kröning R; Jones J A; Hom D K; Chuang C C; Sanga R; Los G; Howell S B; Christen R D
Enhancement of drug sensitivity of human malignancies by epidermal growth factor.
British journal of cancer 1995;72(3):615-9.
1995: Naredi P; Heath D D; Enns R E; Howell S B
Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells.
The Journal of clinical investigation 1995;95(3):1193-8.
1995: McClay E F; Braly P D; Kirmani S; Plaxe S C; Kim S; McClay M E; Wilgus L; Howell S B
A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma.
American journal of clinical oncology 1995;18(1):23-6.
1995: Los G; Blommaert f A; Barton R; Heath D D; den Engelse L; Hanchett C; Vicario D; Weisman R; Robbins K T; Howell S B
Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation.
Cancer chemotherapy and pharmacology 1995;37(1-2):150-4.
1994: Naredi P; Heath D D; Enns R E; Howell S B
Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
Cancer research 1994;54(24):6464-8.
1994: Gately D P; Jones J A; Christen R; Barton R M; Los G; Howell S B
Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo.
British journal of cancer 1994;70(6):1102-6.
1994: Robbins K T; Vicario D; Seagren S; Weisman R; Pellitteri P; Kerber C; Orloff L; Los G; Howell S B
A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer.
American journal of surgery 1994;168(5):419-22.
1994: Jamshidipour R; Pinho E B; Howell S B
In vivo modulation of cisplatin cytotoxicity by the cholecystokinin antagonist MK-329 in human pancreatic cancer xenografts.
Anticancer research 1994;14(6B):2611-6.
1994: Robbins K T; Storniolo A M; Kerber C; Vicario D; Seagren S; Shea M; Hanchett C; Los G; Howell S B
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2113-20.
1994: Kirmani S; Braly P S; McClay E F; Saltzstein S L; Plaxe S C; Kim S; Cates C; Howell S B
A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer.
Gynecologic oncology 1994;54(3):338-44.
1994: McClay E F; Albright K D; Jones J A; Christen R D; Howell S B
Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
British journal of cancer 1994;70(3):449-52.
1994: McClay E F; Braly P D; Kirmani S; Plaxe S C; McClay M E; Wilgus L; Kim S; Howell S B
A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies.
Cancer 1994;74(2):664-9.
1994: Thiebaut F; Enns R; Howell S B
Cisplatin sensitivity correlates with its ability to cause cell cycle arrest via a wee1 kinase-dependent pathway in Schizosaccharomyces pombe.
Journal of cellular physiology 1994;159(3):506-14.
1994: Christen R D; Isonishi S; Jones J A; Jekunen A P; Hom D K; Kröning R; Gately D P; Thiebaut F B; Los G; Howell S B
Signaling and drug sensitivity.
Cancer metastasis reviews 1994;13(2):175-89.
1994: Jekunen A P; Hom D K; Alcaraz J E; Eastman A; Howell S B
Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells.
Cancer research 1994;54(10):2680-7.
1994: Isonishi S; Hom D K; Eastman A; Howell S B
Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line.
British journal of cancer 1994;69(2):217-21.
1994: Jekunen A P; Christen R D; Shalinsky D R; Howell S B
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
British journal of cancer 1994;69(2):299-306.
1994: Jamshidipour R; Pinho E B; Hom D K; Howell S B
Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line.
Cancer chemotherapy and pharmacology 1994;34(6):484-90.
1993: McClay E F; Albright K D; Jones J A; Christen R D; Howell S B
Tamoxifen modulation of cisplatin cytotoxicity in human malignancies.
International journal of cancer. Journal international du cancer 1993;55(6):1018-22.
1993: Kim S; Chatelut E; Kim J C; Howell S B; Cates C; Kormanik P A; Chamberlain M C
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2186-93.
1993: Plaxe S C; Braly P S; Freddo J L; McClay E; Christen R D; Kirmani S; Kim S; Heath D; Howell S B
Phase I and pharmacokinetic study of intraperitoneal ormaplatin.
Gynecologic oncology 1993;51(1):72-7.
1993: Mc Clay E F; Mc Clay M E; Albright K D; Jones J A; Christen R D; Alcaraz J; Howell S B
Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation.
Cancer 1993;72(6):1914-8.
1993: Christen R D; Jekunen A P; Jones J A; Thiebaut F; Shalinsky D R; Howell S B
In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules.
The Journal of clinical investigation 1993;92(1):431-40.
1993: Gately D P; Howell S B
Cellular accumulation of the anticancer agent cisplatin: a review.
British journal of cancer 1993;67(6):1171-6.
1993: Bonetti A; Howell S B; McClay E; Kirmani S; Goel R; Plaxe S; Braly P; Kim S
High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity.
Gynecologic oncology 1993;49(3):318-24.
1993: Jekunen A P; Shalinsky D R; Hom D K; Albright K D; Heath D; Howell S B
Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro.
Biochemical pharmacology 1993;45(10):2079-85.
1993: Kimura E; Enns R E; Alcaraz J E; Arboleda J; Slamon D J; Howell S B
Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):891-8.
1993: McClay E F; Albright K D; Jones J A; Christen R D; Howell S B
Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.
Cancer research 1993;53(7):1571-6.
1993: Kim S; Howell S B; McClay E; Kirmani S; Goel R; Plaxe S; Braly P; Bonetti A
Dose intensification of cisplatin chemotherapy through biweekly administration.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(3):221-7.
1993: Shalinsky D R; Heath D D; Jekunen A P; Alcaraz J E; Howell S B
Selective modulation of vinblastine sensitivity by 1,9-dideoxyforskolin and related diterpenes in multidrug resistant tumour cells.
British journal of cancer 1993;67(3):471-9.
1993: Shalinsky D R; Jekunen A P; Alcaraz J E; Christen R D; Kim S; Khatibi S; Howell S B
Regulation of initial vinblastine influx by P-glycoprotein.
British journal of cancer 1993;67(1):30-6.
1993: Lindnér P; Heath D D; Shalinsky D R; Howell S B; Naredi P; Hafström L
Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide.
Surgical oncology 1993;2(2):105-12.
1993: Kimura E; Enns R E; Thiebaut F; Howell S B
Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line.
Cancer chemotherapy and pharmacology 1993;32(4):279-85.
1993: Kimura E; Howell S B
Analysis of the cytotoxic interaction between cisplatin and hyperthermia in a human ovarian carcinoma cell line.
Cancer chemotherapy and pharmacology 1993;32(6):419-24.
1992: McClay E F; Albright K D; Jones J A; Eastman A; Christen R; Howell S B
Modulation of cisplatin resistance in human malignant melanoma cells.
Cancer research 1992;52(24):6790-6.
1992: Isonishi S; Jekunen A P; Hom D K; Eastman A; Edelstein P S; Thiebaut F B; Christen R D; Howell S B
Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha.
The Journal of clinical investigation 1992;90(4):1436-42.
1992: Robbins K T; Storniolo A M; Kerber C; Seagren S; Berson A; Howell S B
Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies.
Head & neck 1992;14(5):364-71.
1992: McClay E F; Howell S B
Intraperitoneal therapy in the management of patients with ovarian cancer.
Hematology/oncology clinics of North America 1992;6(4):915-26.
1992: Jekunen A; Vick J; Sanga R; Chan T C; Howell S B
Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
Cancer research 1992;52(13):3566-71.
1992: Christen R D; Shalinsky D R; Howell S B
Enhancement of the loss of multiple drug resistance by hydroxyurea.
Seminars in oncology 1992;19(3 Suppl 9):94-100.
1991: Isonishi S; Hom D K; Thiebaut F B; Mann S C; Andrews P A; Basu A; Lazo J S; Eastman A; Howell S B
Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin.
Cancer research 1991;51(21):5903-9.
1991: Shalinsky D R; Slovak M L; Howell S B
Modulation of vinblastine sensitivity by dipyridamole in multidrug resistant fibrosarcoma cells lacking mdr1 expression.
British journal of cancer 1991;64(4):705-9.
1991: Mann S C; Andrews P A; Howell S B
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells.
International journal of cancer. Journal international du cancer 1991;48(6):866-72.
1991: Isonishi S; Kirmani S; Kim S; Plaxe S C; Braly P S; McClay E F; Howell S B
Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole.
Journal of the National Cancer Institute 1991;83(9):621-6.
1991: Howell S B; Isonishi S; Christen R D; Andrews P A; Mann S
Cellular pharmacologic strategies for overcoming drug resistance: potential applications to regional therapy.
The European journal of surgery. Supplement. : = Acta chirurgica. Supplement 1991;(561):45-8.
1991: Kirmani S; Lucas W E; Kim S; Goel R; McVey L; Morris J; Howell S B
A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(4):649-57.
1991: Howell S B; Kirmani S; McClay E F; Kim S; Braly P; Plaxe S
Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.
Seminars in oncology 1991;18(1 Suppl 3):5-10.
1990: Shalinsky D R; Andreeff M; Howell S B
Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro.
Cancer research 1990;50(23):7537-43.
1990: Christen R D; Hom D K; Porter D C; Andrews P A; MacLeod C L; Hafstrom L; Howell S B
Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.
The Journal of clinical investigation 1990;86(5):1632-40.
1990: Isonishi S; Andrews P A; Howell S B
Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate.
The Journal of biological chemistry 1990;265(7):3623-7.
1990: Kirmani S; McVey L; Loo D; Howell S B
A phase I clinical trial of intraperitoneal thiotepa for refractory ovarian cancer.
Gynecologic oncology 1990;36(3):331-4.
1990: Howell S B; Kirmani S; Lucas W E; Zimm S; Goel R; Kim S; Horton M C; McVey L; Morris J; Weiss R J
A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(1):137-45.
1990: Goel R; Andrews P A; Pfeifle C E; Abramson I S; Kirmani S; Howell S B
Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy.
European journal of cancer (Oxford, England : 1990) 1990;26(1):21-7.
1990: Andrews P A; Jones J A; Varki N M; Howell S B
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma.
Cancer communications 1990;2(2):93-100.
1990: Kirmani S; Zimm S; Cleary S M; Mowry J; Howell S B
Extremely prolonged continuous intraperitoneal infusion of cytosine arabinoside.
Cancer chemotherapy and pharmacology 1990;25(6):454-8.
1990: Mann S C; Andrews P A; Howell S B
Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
Cancer chemotherapy and pharmacology 1990;25(4):236-40.
1990: Chan T C; Howell S B
Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity.
European journal of cancer (Oxford, England : 1990) 1990;26(8):907-11.
1990: Katz E J; Vick J S; Kling K M; Andrews P A; Howell S B
Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells.
European journal of cancer (Oxford, England : 1990) 1990;26(6):724-7.
1989: Goel R; Cleary S M; Horton C; Kirmani S; Abramson I; Kelly C; Howell S B
Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin.
Journal of the National Cancer Institute 1989;81(20):1552-60.
1989: Howell S B; Hom D K; Sanga R; Vick J S; Chan T C
Dipyridamole enhancement of etoposide sensitivity.
Cancer research 1989;49(15):4147-53.
1989: Howell S B; Hom D; Sanga R; Vick J S; Abramson I S
Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole.
Cancer research 1989;49(12):3178-83.
1989: Howell S B
Improving the therapeutic index of intra-arterial cisplatin chemotherapy.
European journal of cancer & clinical oncology 1989;25(5):775-6.
1989: Chan T C; Howell S B
Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells.
European journal of cancer & clinical oncology 1989;25(4):721-7.
1989: Andrews P A; Murphy M P; Howell S B
Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells.
European journal of cancer & clinical oncology 1989;25(4):619-25.
1989: Goel R; Cleary S M; Horton C; Balis F M; Zimm S; Kirmani S; Howell S B
Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(2):262-9.
1989: Goel R; Sanga R; Howell S B
Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate.
Cancer chemotherapy and pharmacology 1989;25(3):167-72.
1989: Howell S B; Kirmani S; Goel R
Novel approaches to intraperitoneal drug delivery.
Acta medica Austriaca 1989;16(3-4):61-4.
1988: Mann S C; Andrews P A; Howell S B
Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
Anticancer research 1988;8(6):1211-5.
1988: Howell S B
Intraperitoneal chemotherapy for ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(11):1673-5.
1988: Zimm S; Cleary S M; Horton C N; Howell S B
Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(4):696-700.
1988: Velury S; Howell S B
Measurement of plasma thiols after derivatization with monobromobimane.
Journal of chromatography 1988;424(1):141-6.
1988: Andrews P A; Velury S; Mann S C; Howell S B
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
Cancer research 1988;48(1):68-73.
1988: Chan T C; Coppoc G L; Zimm S; Cleary S; Howell S B
Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients.
Cancer research 1988;48(1):215-8.
1988: Chan T C; Markman M; Pfeifle C E; Taetle R; Abramson I; Howell S B
Uridine pharmacokinetics in cancer patients.
Cancer chemotherapy and pharmacology 1988;22(1):83-6.
1988: Andrews P A; Schiefer M A; Murphy M P; Howell S B
Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion.
Chemico-biological interactions 1988;65(1):51-8.
1988: Howell S B; Goel R
Cytostatic modifiers: current status and considerations for the future.
Acta chirurgica Scandinavica. Supplementum 1988;541():22-31.
1988: Howell S B; Zimm S
Intraperitoneal chemotherapy: application to upper gastrointestinal neoplasms.
Acta chirurgica Scandinavica. Supplementum 1988;541():16-21.
1987: Howell S B; Schiefer M; Andrews P A; Markman M; Abramson I
The pharmacology of intraperitoneally administered bleomycin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(12):2009-16.
1987: Howell S B; Zimm S; Markman M; Abramson I S; Cleary S; Lucas W E; Weiss R J
Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(10):1607-12.
1987: Zimm S; Cleary S M; Lucas W E; Weiss R J; Markman M; Andrews P A; Schiefer M A; Kim S; Horton C; Howell S B
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide.
Cancer research 1987;47(6):1712-6.
1987: Markman M; Chan T C; Cleary S; Howell S B
Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
Cancer chemotherapy and pharmacology 1987;19(1):80-3.
1986: Chan T C; Markman M; Cleary S; Howell S B
Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Cancer research 1986;46(6):3168-72.
1985: Markman M; Cleary S; Lucas W E; Howell S B
Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(7):925-31.

Sign-in to see more